The Inhalation CDMO Global Market Report 2024 by The Business Research Company provides market overview across 60+ geographies in the seven regions – Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa, encompassing 27 major global industries. The report presents a comprehensive analysis over a ten-year historic period (2010-2021) and extends its insights into a ten-year forecast period (2023-2033).
Learn More On The Inhalation CDMO Market:
https://www.thebusinessresearchcompany.com/report/inhalation-cdmo-global-market-report
According to The Business Research Company’s Inhalation CDMO Global Market Report 2024, The inhalation CDMO market size is expected to see strong growth in the next few years. It will grow to $2.7 billion in 2028 at a compound annual growth rate (CAGR) of 6.8%. The growth in the forecast period can be attributed to focus on precision medicine and targeted therapies, rapid expansion of biopharmaceutical inhalation therapies,focus on patient-centric solutions, global market expansion and emerging market opportunities, regulatory support for inhalation drug development. Major trends in the forecast period include increasing demand for digital health solutions, biologic inhalation therapies, focus on sustainable inhaler technologies, integration of artificial intelligence (AI) and machine learning, collaborations and partnerships.
The increasing prevalence of respiratory disorders is expected to propel the growth of the inhalation CDMO market going forward. Respiratory disorders are a group of medical conditions that affect the respiratory system, which includes the organs and structures involved in breathing. Inhalation CDMOs are used in the development and manufacturing of products for respiratory disorders due to their expertise in formulating and delivering drugs to the lungs, offering specialized expertise, infrastructure, and resources to pharmaceutical companies seeking to bring innovative inhalation therapies. For instance, in June 2023, according to reports shared by the Australian Institute of Health and Welfare, an Australia-based national agency, there was a rise in respiratory disease-related deaths from 43,031 in 2020 to 46,551 in 2021in Australia. Furthermore, in September 2022, according to the data published by The Lancet, a UK-based book and periodic data publishing organization, 11,255 new cases of RSV were recorded in 2021, which is 11.4% more compared to 9,972 cases in 2020. Therefore, the increasing prevalence of respiratory disorders is driving the growth of the inhalation CDMO market.
Get A Free Sample Of The Report (Includes Graphs And Tables):
https://www.thebusinessresearchcompany.com/sample.aspx?id=13864&type=smp
The inhalation cdmo market covered in this report is segmented –
1) By Product: Dry Powder Inhaler (DPIs), Metered Dose Inhaler (MDIs), Nebulizer, Soft Mist Inhaler
2) By Disease Indication: Asthma, Chronic Obstructive Pulmonary Disease (COPD), Pulmonary Arterial Hypertension, Acute Respiratory Distress Syndrome, Pulmonary Fibrosis
3) By Technology: Manual Inhalers (SMI), Digital Inhalers
4) By End-User: Big Pharmaceutical Companies, Small and Medium-sized Pharmaceutical Companies, Generic Pharmaceutical Companies, Other End-Users
Major companies operating in the inhalation CDMO industry are adopting a strategic partnership approach to provide specialized drug development and delivery. A strategic partnership is a long-term, mutually beneficial arrangement between two or more companies that work together to achieve shared goals. For instance, in May 2023, Hovione, a Portugal-based Contract Development and Manufacturing Organization, partnered with H&T Presspart, a UK-based manufacturer of high-precision metal and plastic components for the pharmaceutical industry, to develop Presspart’s Sunrise Capsule-based Dry Powder Inhaler platform. This partnership focuses on developing new technologies that can deliver higher doses of drugs and improve the efficiency of drug delivery to the lungs.
The inhalation cdmo market report table of contents includes:
1. Executive Summary
2. Inhalation CDMO Market Characteristics
3. Inhalation CDMO Market Trends And Strategies
4. Inhalation CDMO Market – Macro Economic Scenario
5. Global Inhalation CDMO Market Size and Growth
.
.
.
26. South America Inhalation CDMO Market
27. Brazil Inhalation CDMO Market
28. Middle East Inhalation CDMO Market
29. Africa Inhalation CDMO Market
30. Inhalation CDMO Market Competitive Landscape And Company Profiles
Top Major Players:
- Pfizer Inc
- Merck KGaA
- Baxter’s BioPharma Solutions
- Lonza Group AG
- Catalent Inc
Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: [email protected]
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
